Ixinity Market Report 2026

Ixinity Market Overview

• The Ixinity market growth in the historic period has been driven by genetic prevalence of hemophilia b, limitations of plasma-derived factors • Market expansion is supported by adoption of extended half-life therapies, expansion of homecare treatment • Growth Driver: The Rising Prevalence Of Hemophilia Fuels Ixinity Market Growth Prospects • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ixinity Market?

Ixinity is a recombinant clotting factor IX used to treat hemophilia B, a genetic bleeding disorder. It is designed to replace the deficient or absent factor IX in patients, helping to prevent and control bleeding episodes. Ixinity is produced using advanced biotechnology to ensure a high level of purity and efficacy. The drug is typically administered through intravenous infusion. It offers a long-acting option, reducing the frequency of infusions required for maintaining factor IX levels. The main indication types of ixinity are routine prophylaxis, on-demand treatment, and perioperative management. Routine prophylaxis involves regularly scheduled treatments to prevent bleeding episodes in individuals with hemophilia. The patient demographics include pediatric patients, adult patients, and high-risk groups, and various end users are hospitals, clinics, hemophilia treatment centers, and home care settings.

What Is The Ixinity Market Growth Forecast?

The growth in the forecast period can be attributed to adoption of extended half-life therapies, expansion of homecare treatment, increasing hemophilia awareness, supportive rare disease reimbursement, innovation in clotting factor engineering. Major trends in the forecast period include shift toward long-acting factor ix therapies, expansion of prophylactic hemophilia care, personalized bleeding disorder management, growth of home infusion programs, improved recombinant protein purity.

Global Ixinity Market Segmentation

1) By Indication: Routine Prophylaxis, On-Demand Treatment, Perioperative Management 2) By Patient Demographics: Pediatric Patients, Adult Patients, High-Risk Groups 3) By End Users: Hospitals, Clinics, Hemophilia Treatment Centers, Home Care Settings

What Are The Drivers Of The Ixinity Market?

The rising prevalence of hemophilia is expected to propel the growth of the ixinity market going forward. Hemophilia refers to an inherited bleeding disorder where blood fails to clot properly, leading to excessive bleeding from injuries or spontaneously, often requiring medical treatment. Rising hemophilia cases are due to genetic factors, increased recognition of acquired forms, and improved diagnostic practices, leading to better identification of previously undiagnosed individuals. Ixinity is used in the treatment of hemophilia B to prevent and control bleeding episodes. It is a recombinant factor IX therapy that helps manage clotting deficiencies in individuals with hemophilia B. For instance, in October 2023, according to the World Federation of Hemophilia, a Canada-based non-profit organization, the estimated prevalence of hemophilia is around 17.1 per 100,000 males for hemophilia A and 3.8 per 100,000 for hemophilia B, with severe cases much rarer at 6.0 and 1.1 per 100,000, respectively, resulting in approximately 830,895 patients globally, including 282,266 with severe forms, and over 257,146 identified cases of hemophilia, including 208,957 hemophilia A and 42,203 hemophilia B cases, along with more than 100,000 cases of von Willebrand disease. Therefore, the rising prevalence of hemophilia is driving the growth of the ixinity industry. The increasing aging population is expected to ignite the growth of the ixinity market going forward. The aging population refers to the increasing proportion of elderly individuals in a population due to declining birth rates and rising life expectancy, impacting healthcare and social systems. The aging population is increasing due to advancements in healthcare extending life expectancy and declining birth rates reducing the proportion of younger individuals. Ixinity benefits aging individuals with hemophilia B by managing bleeding risks associated with age-related health challenges, ensuring stable clotting factor IX levels. For instance, in January 2024, according to the statistics published by the Population Reference Bureau (PRB), a US-based nonprofit organization, it is anticipated that the number of Americans 65 and older will climb from 58 million in 2022 to 82 million in 2050 (a 47% increase) and that their proportion of the overall population will increase from 17% to 23%. Therefore, the increasing aging population is driving the growth of the ixinity industry.

Key Players In The Global Ixinity Market

Major companies operating in the ixinity market are Medexus Pharma Inc.

What Are Latest Mergers And Acquisitions In The Ixinity Market?

In March 2023, XOMA Corporation, a US-based biotechnology company, acquired the commercial payment and a portion of the milestone rights to IXINITY from Aptevo Therapeutics for an undisclosed amount. This acquisition aligns with XOMA's strategy to build a consistent incoming cash flow and supports its goal of accelerating royalty aggregation. Aptevo Therapeutics Inc. is a US-based clinical-stage biotechnology company that develops immuno-oncology therapies to treat cancer.

Regional Insights

North America was the largest region in the ixinity market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ixinity Market?

The Ixinity market consists of sales of Ixinity (recombinant coagulation factor IX). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ixinity Market Report 2026?

The ixinity market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ixinity industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.